GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » Ending Cash Position

MIRA (Mira Pharmaceuticals) Ending Cash Position : $2.82 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mira Pharmaceuticals Ending Cash Position?

Mira Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2024 was $2.82 Mil.

Mira Pharmaceuticals's quarterly Ending Cash Position declined from Dec. 2023 ($4.60 Mil) to Mar. 2024 ($3.53 Mil) and declined from Mar. 2024 ($3.53 Mil) to Jun. 2024 ($2.82 Mil).

Mira Pharmaceuticals's annual Ending Cash Position declined from Dec. 2021 ($2.81 Mil) to Dec. 2022 ($0.35 Mil) but then increased from Dec. 2022 ($0.35 Mil) to Dec. 2023 ($4.60 Mil).

Mira Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Mira Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Ending Cash Position Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Ending Cash Position
2.81 0.35 4.60

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.03 5.87 4.60 3.53 2.82

Mira Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Mira Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.351+4.252
=4.60

Mira Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.529+-0.705
=2.82

Mira Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Mira Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » Ending Cash Position
Comparable Companies
XKRX:035080 XKRX:026040 XKRX:005360 XKRX:204020 XKRX:366030 XKRX:215480 XKRX:019010 XKRX:027410 XKRX:067830 XKRX:037710 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN
Traded in Other Exchanges
K6S:Germany
Address
855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
Website
https://www.mirapharmaceuticals.com
Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.
Executives
Brian Patrick Mcnulty 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Frederick Daly director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
George Cappy 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
David C Vorhoff director C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Chapman Christopher C Jr director, officer: Executive Chairman C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Adam Kaplin officer: Pres. & Chief Scientific Off. C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Michelle Yanez officer: CFO, Secretary & Treasurer 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Hugh Iii Mccoll director 100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202
Christos Nicholoudis director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bradley Kroenig director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Erez Aminov director, officer: Chief Executive Officer C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Talhia Tuck director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bay Shore Trust 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173